Efficacy of trazodone in the treatment of Insomnia;Skuteczność trazodonu w leczeniu bezsenności

Polski Merkuriusz Lekarski

Volumn 28, Issue 168, 2010, Pages 509-512

  GaŁecki, Piotr ^a   Florkowski, Antoni ^a   Talarowska, Monika ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Insomnia; Trazodone

Indexed keywords

ANTIDEPRESSANT AGENT; TRAZODONE;

ARTICLE; DEPRESSION; HUMAN; INSOMNIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; HUMANS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRAZODONE;

EID: 77954679906     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Aloia M.S., Amedt J.T., Davis J.D., i wsp.: Neuropsychological sequelae of obstructive sleep apnea syndrome: a critical review. J. Int. Neuropsychol. Soc., 2004, 10, 772-785.
2. Armitage R.: The effects of antidepressants on sleep in patients with depression. Can. J. Psychiatry, 2000, 45, 803-809.
3. Badzio-Jagiello H.: Analiza przebiegu snu jako czynnik różnicuja̧cy najczȩstsze zespoŁy psychopatologlczne u pacjentów hospitalizowanych. Sen, 2002, 2, 1-14.
4. Benca R.M., Ancoli-lsrael S., Moldofsky H.: Special considerations in insomnia diagnosis and management: depressed, elderly and chronic pain population. J. Clin. Psychiatry, 2004, 65, 26-35.
5. Bernert R.A., Joiner T.R., Cukrowicz K.C. i wsp.: Suicidality and sleep disturbances. Sleep, 2005, 28, 1135-1141.
6. Bertschya G., Ragama-Pardosa E., Muscionicoa M. I wsp.: Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a seminaturalistic study. Pharmacological Research, 2005, 51, 79-84.
7. Bilyukov R., Georgiev O.B., Petrova D.S. i wsp.: Obstructive sleep apnea syndrome and depressive symptoms. Folia Med., 2009, 51, 18-24.
8. Boeve B.F., Silber M.H., Ferman T.J.: Current management of sleep disturbances in dementia. Current Neurology and Neuroscience Reports, 2002, 2, 169-177.
9. Breslau N., Roth T., Rosenthal L. i wsp.: Sleep disturbances and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. Psychiatry, 1996, 39, 411-418.
10. Buysee D.J, Reynolds CF., Kupfer D.J. i wsp.: Clinical diagnosis in 216 insomnia patients using the ICSD, DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep, 1994, 17, 630-637.
11. Chellappa S.L., Araujo J.F.: Sleep disorders and suicidal ideation in patients with depressive disorder. Psychiatry Res., 2007, 153, 131-136.
12. Duman R.: Neural plasticity: consequences of stress and actions of antidepressant treatment. Dialogues Clin. Neurosci., 2004, 6, 157-169.
13. Fudge J.L., Perry P.J., Garvey M.J. i wsp.: A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J. Affective Dis., 1990, 18, 275-280.
14. Fujino Y., Mizoue T., Tokui N. i wsp.: Prospective Cohort Study of Stress, Life Satisfaction, Self-Rated Health, Insomnia and suicide death in Japan. Suicide Life Threat. Behav., 2005, 35, 227-237.
15. GaŁecki P., Zboralski K., Florkowski A.: Skuteczność i bezpieczeństwo trazodonu w leczeniu zaburzeń adaptacyjnych - badania naturalistyczne. Pol. Merk. Lek., 2005, 110, 183-187.
16. Grotthus B., Radzik J., Leszek J.: Trazodon w psychogeriatrii. Psychogeriatr. Pol., 2004, 1, 51-58
17. Haria M., Fitton A., McTavish D.: Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging, 1994, 4, 331-355.
18. International Classification of Sleep Disorder 2nd: Diagnostic and coding manual, American Academy of Sleep Medicine. Westchester, IL 2005.
19. Jakitowicz J., Wiśniewski G., Nowicki Z. i wsp.: Polietiologiczne uwarunkowanie zaburzeń snu na podstawie analizy przyjȩć pacjentów w poradni zaburzeń snu. Sen, 2002, 2, 53-59.
20. Jindal R.: Insomnia in patients with depression: some pathophysiological and treatment consideration. CNS Drugs, 2009, 23, 309-329.
21. Jindal R., Thase M.: Treatment of insomnia associated with clinical depression. Sleep Medicine Reviews, 2004, 8, 19-30.
22. Kamba, M., Inoue Y., Higami S. I wsp.: Cerebral metabolic impairment in patients with obstructive sleep apnoea: an independent association of obstructive sleep apnoea whit white matter change. J. Neurol. Neurosurg. Psychiatry, 2001, 71, 334-339.
23. Kaynak H., Kaynak D., Gozukirmizi E. i wsp.: The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Medicine, 2004, 5, 15-20.
24. Krishnan P., Hawranik P.: Diagnosis and management of geriatric insomnia: A guide for nurse practitioners. J. Am. Acad. Nurs. Pract, 2008, 20, 590-599.
25. Krysiak K., Jarema M.: Depresja ibezsenność. Wiadomości Psychiatryczne, 2006, 9, 99-108.
26. Landowski J., Cubata W.J.: Trazodon - charakterystyka kliniczna i farmakologiczna. Psychiatria, 2005, 2, 135-144.
27. Le Bon O., Murphy J.R., Staner L. i wsp.: Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: Polysomnographie and clinical evaluations. J. Clin. Psychopharmacol., 2003, 23, 377-83.
28. Lebert F., Pasquier F., Petit H.: Behavioral effects of trazodone in Alzheimers disease. J. Clin. Psychiatry, 1994, 55, 536-538.
29. Lebert F., Stekke W., Hasenbroekx C i wsp.: Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord., 2004, 17, 355-359.
30. Liu X., Buysse D.J.: Sleep and youth suicidal behavior a neglected field. Curr. Opin. Psychiatry, 2006, 19, 288-293.
31. Makowska I., Magierski R., Kloszewska I.: Trazodon w leczeniu zaburzeń zachowania i objawów psychotycznych towarzysza̧cych otȩpieniu. Farmakoterapia w Psychiatrii i Neurologii, 2004, 4, 485-494.
32. Miȩdzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych. Rewizja dziesia̧ta. RozdziaŁ V: Zaburzenia psychiezne i zachowania. Uniwersyteckie Wydawnictwo Medyczne .,Vesalius", Kraków, 1994.
33. Murawiec S.: Leczenie depresji w nowym ujȩdu. Psychiatria, 2005, 3, 13-24.
34. Nierenberg A.A., Adler L.A., Peselow E. i wsp.: Trazodone for antidepressant-associated insomnia. Am. J. Psychiatry, 1994, 151, 1069-1072.
35. Ohayon M.M., Caulet M-, Lemoine P.: Comorbidity of mental and insomnia disorders in the general population. Compr. Psychiatry, 1998, 39, 185.197.
36. Ohayon M.M.: Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev., 2002, 6, 97-111.
37. Ohayon M.M., Roth T: Place of chronic insomnia in the course of depressive and anxiety disorders. J. Psychiatr. Res., 2003, 37, 9-15.
38. Perlis M.L., Giles D.E., Buysse D.J. i wsp.: Self-reported sleep disturbances as a prodromal symptom in recurrent depression. J. Affect. Disord., 1997, 42, 209-212.
39. Reynolds C.F., Kupfer D.J., McEachran A.B. i wsp.: Coble P.A., Depressive psychopathology in male sleep apneics. J. Clin. Psychiatry, 1984, 45, 287-290.
40. Richardson G.S., Roth T.: Future directions In the management of insomnia. J. Clin. Psychiatry, 2001, 62, 39-45.
41. Roth T., Hajak G., Ustun TB.: Consensus for the pharmacological management of insomnia in the new millennium. International Journal of Clinical Practice, 2001, 55, 42-52.
42. Roth T., Roehrs T: Insomnia: epidemiology, characteristics and consequences. Clin. Cornestrone, 2003, 5, 5-15.
43. Rotzinger S., Fang J., Baker G.B.: Trazodone is metabolized to mochlorophenylpiperazine by CYP3A4 from human sources. Drug Metab. Discos., 1998, 26, 572-575.
44. Salazar-Grueso E.F., Rosenberg R.S., Roos R.P.: Sleep apnea in olivopontocerebellar degeneration: treatment with trazodone. Ann. Neurol., 1988, 23, 399-401.
45. Saletu B., Prause W., Anderer P. i wsp.: Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the somnolyzer 24x7 and the siesta database. Neuropsychobiology, 2005, 51, 148-163.
46. Saletu-Zyhlarz G.M., Abu-Bakr M.H., Anderer P. i wsp.: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog. Neuropsychopharmacol Biol. Psychiatry, 2002, 26, 249-260.
47. Saletu-Zyhlarz G.M., Anderer P., Arnold O. i wsp.: Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology, 2003, 48, 194-208.
48. Sassi R.B., Brambilla P., Nicoletti M. i wsp.: White matter hyperintensities in bipolar and uni-polar patients with relatively mild to moderate illness severity. J. Affect. Disord., 2003, 77, 237-245.
49. Sateia M.J., Doghramji K., Hauri P.J. i wsp.: Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep, 2000, 23, 243-308.
50. Scharf M.B., Sachais B.A.: Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J. Clin. Psychiatry, 1990, 51, 13-17.
51. Sforza E., de Saint Hilaire Z., Pelissolo A. i wsp.: Personality, anxiety and mood traits in patients with sleep related breathing disorders: effect of reduced daytime alertness. Sleep Med., 2002, 3, 139-145.
52. Sharpley A.L., Gregory C.A., Solomon R.A. i wsp.: Slow wave sleep and 5-HT2 receptor sensitivity during maintenance tricyclic antidepressant treatment. J. Affect. Disord., 1990, 19, 273-277.
53. Singareddy R.K., Balon R.: Sleep and suicide in psychiatric patients. Ann. Vlin. Psychiatry, 2001, 13, 93-101.
54. Skalski M.: Sen ijego zaburzenia. Przew. Lek., 2003, 6, 3, 128-133.
55. Stoller M.K.: Economic Effects of insomnia. Clin. Therap., 1994, 16, 873-897.
56. Szelenberger W.: Standardy leczenla bezsenności Polskiego Towarzystwa Badań nad Snem. Sen, 2006, 6, 1-10.
57. Sznydler J., Skórzewska A., Ptaźnik A.: Leki blokuja̧ce receptory serotoninowe oraz hamuja̧ce wychwyt zwrotny serotoniny (SARI) w terapii zaburzeń psychicznych. Farmakoterapia w Psychiatrii i Neurologii, 2003, 39-51.
58. Vail-Smith K., Felts W.M., Becker C.: Relationship between sleep quality and health risk behaviors in undergraduated college students. Col. Stud. J., 2009, 43, 924-930.
59. Veasey S.C.: Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am. J. Resp. Med., 2003, 2, 21-29.
60. Vgontzas A.N., Pejovic S., Zoumakis E. i wsp.: Hypothalamic- pituitaryadrenal axis activity in obese men with and without sleep apnea: effects on continuous positive airway pressure therapy. J. Clin. Endocin. Metab., 2007, 92, 4199-4207.
61. Walsh J.: Drugs used to treat insomnia in 2002: Regulatory-based rather than evidence-based medicine. Sleep, 2004, 27, 8, 1441-1442.
62. Ware J.C., Pittard J.T.: Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J. Clin. Psychiatry, 1990, 51, 9, 18-22.
63. Wichniak A., Wierzbicka A., Sobańska A.: Skuteczność trazodonu w leczeniu bezsenności pierwotnej u pacjentów nieprzyjmuja̧cych leków nasennych i przyjmuja̧cych je w przeszŁości. Pol. Merk. Lek., 2007, 23, 133, 41.
64. Winokur A., Gary K.A., Rodner S. i wsp.: Depression, sleep physiology and antidepressant drugs. Depression and Anxiety, 2001, 14, 19-28.
65. Yamadera H., Nakamura S., Suzuki H. i wsp.: Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry and Clinical Neuroscience, 1998, 52, 439-443.